Analyzing NewLink Genetics (NASDAQ:NLNK) & Editas Medicine (EDIT) – Week Herald
Week Herald |
Analyzing NewLink Genetics (NASDAQ:NLNK) & Editas Medicine (EDIT)
Week Herald It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 … Financial Newsletter – Zacks |
